Short description
Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases.
Description
Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
New York, New York, United States, North America
Founded on
January 1, 2006
Exited on
August 6, 2006
Went public on
August 6, 2006
Stock symbol
AVXL
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Cannot Access
Sign in for full access
Founders
Tom Skarpelos